COMMUNIQUÉS West-GlobeNewswire

Addex Trading Update: Completes 2018 with Strong Cash Position
07/01/2019
Geneva, Switzerland, 7th January 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that it has completed the year 2018 with [...]
Innate Pharma : Upcoming investor conferences
07/01/2019
UPCOMING INVESTOR CONFERENCES Marseille, France, January 7, 2019, 7:00 AM CET Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces that it will be present at the following investor [...]
Innate Pharma : Prochains rendez-vous investisseurs
07/01/2019
PROCHAINS RENDEZ-VOUS INVESTISSEURS Marseille, le 7 janvier 2019, 7h00 CET Innate Pharma SA (Euronext Paris : FR0010331421 – IPH) annonce aujourd’hui qu’elle sera présente aux événements investisseurs suivants : LifeSci [...]
Xenon Pharmaceuticals Outlines 2019 Key Milestones
07/01/2019
Innovative Product Pipeline Includes Multiple Neurology-Focused Products Anticipated to be in Phase 2 or Later Stage Development in 2019 BURNABY, British Columbia, Jan. 06, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals [...]
Adverum Biotechnologies Provides 2019 Outlook
07/01/2019
Advancing Novel Gene Therapy ADVM-022 for Wet AMD in OPTIC Phase 1 Clinical Trial MENLO PARK, Calif., Jan. 06, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company [...]
Oxford Immunotec Announces Board Approval of $100 Million Share Repurchase Program and Reaffirms Growth Expectations for Fourth Quarter 2018
07/01/2019
OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 06, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that its Board of [...]
Galapagos initiates NOVESA Phase 2a trial in patients with systemic sclerosis
06/01/2019
Mechelen, Belgium; 6 January 2019, 22.01 CET - Galapagos NV (Euronext & NASDAQ: GLPG) expands its clinical study program with GLPG1690 in systemic sclerosis, following the recent start of the ISABELA Phase 3 program [...]
Adamas Provides Preliminary Fourth Quarter and Full-Year 2018 GOCOVRI™ Sales Results and Outlines Key Priorities for 2019
06/01/2019
-- GOCOVRI preliminary net sales of approximately $13.3 million for the fourth quarter of 2018 and approximately $34 million for the year -- -- Preliminary total prescriptions of approximately 5,700 for the fourth [...]
Gritstone Oncology Announces Updated Presentation Time at the 37th Annual J.P. Morgan Healthcare Conference
06/01/2019
EMERYVILLE, Calif., Jan. 06, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, [...]
Executive Women In Bio Releases First Annual Directory of Boardroom Ready Executive Profiles
05/01/2019
Applications for the 2019 Boardroom Ready program now open NEW YORK, Jan. 05, 2019 (GLOBE NEWSWIRE) -- Executive Women In Bio (EWIB), a committee comprised of senior leaders in biopharma and the life sciences operating [...]
CORRECTING and REPLACING -- Unum Therapeutics Announces 2019 Goals and Expected Milestones
05/01/2019
In a release issued yesterday under the same headline by Unum Therapeutics Inc. (NASDAQ: UMRX), please note the anticipated 2019 milestone for BOXR1030 has been changed from initiating clinical development to initiating [...]
ChemioCare Initiates Development Program in Pediatric CINV
04/01/2019
NEW YORK, Jan. 04, 2019 (GLOBE NEWSWIRE) -- ChemioCare USA Inc. (“ChemioCare” or the “Company”), a platform company focused on proprietary transdermal delivery today announced that its Adult Ondansetron 5-day adhesive [...]
Arvinas Receives Authorization to Proceed for its IND Application for PROTAC™ Therapy to Treat Patients with Metastatic Castration-Resistant Prostate Cancer
04/01/2019
Expects Enrollment of Phase 1 Trial to Begin in the First Quarter of 2019 NEW HAVEN, Conn., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on [...]
Poseida Therapeutics Appoints Two Independent Directors, Adding Leaders for Compensation and Governance Functions
04/01/2019
SAN DIEGO, Jan. 04, 2019 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. , a clinical-stage biopharmaceutical company leveraging proprietary non-viral gene engineering technologies to create life-saving therapeutics, [...]
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/01/2019
BURLINGTON, Mass., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to four new employees for an aggregate of 53,700 shares of common stock. [...]
Amarin Provides Preliminary 2018 Results and 2019 Outlook
04/01/2019
U.S. Sales Force Increased to 400 Sales Professionals for 2019 Following Unprecedented Positive Results of Vascepa® Cardiovascular Outcomes Study Presented in November 2018 Unaudited Full-Year 2018 Net Total Revenue [...]
Atara Biotherapeutics to Participate in the 37th Annual J.P. Morgan Healthcare Conference
04/01/2019
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with [...]
Fibrocor and Galapagos sign partnership in fibrosis
04/01/2019
Mechelen, Belgium; 4 January 2019, 22.01 CET - Fibrocor Therapeutics L.P. (Fibrocor), a privately held Canadian company, and Galapagos NV (Euronext & NASDAQ: GLPG) announced a global partnership focused on a novel [...]
Candel Therapeutics Completes $28.7 Million Series B Financing
04/01/2019
Proceeds to Accelerate Enrollment of Phase 3 Localized Prostate Cancer Clinical Trial and to Advance Late Stage High-Grade Glioma Clinical Program Candel to Expand Clinical Trials in Other Indications AUBURNDALE, Mass [...]

Pages